Mobile website
Guideline
New criteria for evaluating efficiency of cancer immunotherapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Cancer immunotherapy has been widely accepted in clinic and has been applied for treatment of multiple malignancies in recent years. Different from chemotherapy, most patients can well tolerate immunotherapy and benefit from the improvement of life quality after immunotherapy; furthermore, immunotherapy shows lower risk of severe toxic side effects. Regrettably, disappointing results always occur when the conventional response evaluation criteria are used to assess the clinical efficiency of cancer immunotherapy, which might be responsible for the failure of quite a number of phase Ⅲ clinical trials of cancer immunotherapy. Since it is very difficult to use the existing WHO and RECIST criteria for accurate elucidation and evaluation of the clinical responses to cancer immunotherapy, Dr. Wolchok of New York Memorial Sloan-Kettering Cancer Center and his colleagues published a paper in Clinical Cancer Research in 2009, entitled "Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria", in which a novel response evaluation criterion system was proposed for cancer immunotherapy, and the clinical application of this system was discussed thoroughly. This paper briefly introduces the hot issue in onclology- "new evaluation criteria for efficiency of cancer immunotherapy".
Keywords:
Project Supported:
Project supported by the National Natural Science Foundation of China (No. 30872986/H1611)
Clc Number:
